Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (121-130 of 244) with videos related to

Pageof 25
Sort By:
Cancer Immunology, Immunotherapy : CII|April 11, 2023
CD33 BiTE<sup>®</sup> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.
Nature Medicine|July 8, 2024
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapyDavid M Cordas Dos Santos, Tobias Tix, Roni Shouval, et al.
Hematological Oncology|June 29, 2023
Cellular therapy in lymphomaAnna Sureda, Pieternella J Lugtenburg, Marie José Kersten, et al.
Transplantation|October 25, 2006
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantationMarion Subklewe, René Marquis, Sylvain Choquet, et al.
Haematologica|May 13, 2014
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapseMax Hubmann, Thomas Köhnke, Eva Hoster, et al.
Cancer Immunology, Immunotherapy : CII|May 8, 2023
Correction to: CD33 BiTE<sup>®</sup> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2020
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomasMartin F Orth, Veit Leonhard Buecklein, Eric Kampmann, et al.
Annals of Hematology|February 25, 2012
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patientsAnnika Dufour, Friederike Schneider, Eva Hoster, et al.
Plos One|March 21, 2015
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingBinje Vick, Maja Rothenberg, Nadine Sandhöfer, et al.
Pageof 25

Showing results (121-130 of 244) with videos related to

Sort By:
Pageof 25
Cancer Immunology, Immunotherapy : CII|April 11, 2023
CD33 BiTE<sup>®</sup> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.
Nature Medicine|July 8, 2024
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapyDavid M Cordas Dos Santos, Tobias Tix, Roni Shouval, et al.
Hematological Oncology|June 29, 2023
Cellular therapy in lymphomaAnna Sureda, Pieternella J Lugtenburg, Marie José Kersten, et al.
Transplantation|October 25, 2006
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantationMarion Subklewe, René Marquis, Sylvain Choquet, et al.
Haematologica|May 13, 2014
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapseMax Hubmann, Thomas Köhnke, Eva Hoster, et al.
Cancer Immunology, Immunotherapy : CII|May 8, 2023
Correction to: CD33 BiTE<sup>®</sup> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cellsAnetta Marcinek, Bettina Brauchle, Lisa Rohrbacher, et al.
Blood Advances|July 6, 2022
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapyKai Rejeski, Andreas Burchert, Gloria Iacoboni, et al.
Cancer Immunology, Immunotherapy : CII|March 31, 2020
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomasMartin F Orth, Veit Leonhard Buecklein, Eric Kampmann, et al.
Annals of Hematology|February 25, 2012
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patientsAnnika Dufour, Friederike Schneider, Eva Hoster, et al.
Plos One|March 21, 2015
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imagingBinje Vick, Maja Rothenberg, Nadine Sandhöfer, et al.
Pageof 25